112 related articles for article (PubMed ID: 27889311)
1. Structural evaluation of a nanobody targeting complement receptor Vsig4 and its cross reactivity.
Wen Y; Ouyang Z; Schoonooghe S; Luo S; De Baetselier P; Lu W; Muyldermans S; Raes G; Zheng F
Immunobiology; 2017 Jun; 222(6):807-813. PubMed ID: 27889311
[TBL] [Abstract][Full Text] [Related]
2. NIRF-Molecular Imaging with Synovial Macrophages-Targeting Vsig4 Nanobody for Disease Monitoring in a Mouse Model of Arthritis.
Zheng F; Luo S; Ouyang Z; Zhou J; Mo H; Schoonooghe S; Muyldermans S; De Baetselier P; Raes G; Wen Y
Int J Mol Sci; 2019 Jul; 20(13):. PubMed ID: 31288389
[TBL] [Abstract][Full Text] [Related]
3. Monitoring liver macrophages using nanobodies targeting Vsig4: concanavalin A induced acute hepatitis as paradigm.
Zheng F; Devoogdt N; Sparkes A; Morias Y; Abels C; Stijlemans B; Lahoutte T; Muyldermans S; De Baetselier P; Schoonooghe S; Beschin A; Raes G
Immunobiology; 2015 Feb; 220(2):200-9. PubMed ID: 25440182
[TBL] [Abstract][Full Text] [Related]
4. Protective role of V-set and immunoglobulin domain-containing 4 expressed on kupffer cells during immune-mediated liver injury by inducing tolerance of liver T- and natural killer T-cells.
Jung K; Kang M; Park C; Hyun Choi Y; Jeon Y; Park SH; Seo SK; Jin D; Choi I
Hepatology; 2012 Nov; 56(5):1838-48. PubMed ID: 22711680
[TBL] [Abstract][Full Text] [Related]
5. VSIG4, a B7 family-related protein, is a negative regulator of T cell activation.
Vogt L; Schmitz N; Kurrer MO; Bauer M; Hinton HI; Behnke S; Gatto D; Sebbel P; Beerli RR; Sonderegger I; Kopf M; Saudan P; Bachmann MF
J Clin Invest; 2006 Oct; 116(10):2817-26. PubMed ID: 17016562
[TBL] [Abstract][Full Text] [Related]
6. Induction of T cells suppression by dendritic cells transfected with VSIG4 recombinant adenovirus.
Xu S; Sun Z; Li L; Liu J; He J; Song D; Shan G; Liu H; Wu X
Immunol Lett; 2010 Jan; 128(1):46-50. PubMed ID: 19914289
[TBL] [Abstract][Full Text] [Related]
7. A role of macrophage complement receptor CRIg in immune clearance and inflammation.
He JQ; Wiesmann C; van Lookeren Campagne M
Mol Immunol; 2008 Oct; 45(16):4041-7. PubMed ID: 18752851
[TBL] [Abstract][Full Text] [Related]
8. A potent complement factor C3-specific nanobody inhibiting multiple functions in the alternative pathway of human and murine complement.
Jensen RK; Pihl R; Gadeberg TAF; Jensen JK; Andersen KR; Thiel S; Laursen NS; Andersen GR
J Biol Chem; 2018 Apr; 293(17):6269-6281. PubMed ID: 29497000
[TBL] [Abstract][Full Text] [Related]
9. Molecular imaging with macrophage CRIg-targeting nanobodies for early and preclinical diagnosis in a mouse model of rheumatoid arthritis.
Zheng F; Put S; Bouwens L; Lahoutte T; Matthys P; Muyldermans S; De Baetselier P; Devoogdt N; Raes G; Schoonooghe S
J Nucl Med; 2014 May; 55(5):824-9. PubMed ID: 24686780
[TBL] [Abstract][Full Text] [Related]
10. Human Dendritic Cells Express the Complement Receptor Immunoglobulin Which Regulates T Cell Responses.
Munawara U; Perveen K; Small AG; Putty T; Quach A; Gorgani NN; Hii CS; Abbott CA; Ferrante A
Front Immunol; 2019; 10():2892. PubMed ID: 31921153
[TBL] [Abstract][Full Text] [Related]
11. To be or not to be B7.
Zang X; Allison JP
J Clin Invest; 2006 Oct; 116(10):2590-3. PubMed ID: 17016555
[TBL] [Abstract][Full Text] [Related]
12. VSIG4 interaction with heparan sulfates inhibits VSIG4-complement binding.
Ebstein SY; Rafique A; Zhou Y; Krasco A; Montalvo-Ortiz W; Yu L; Custodio L; Adam RC; Bloch N; Lee K; Adewale F; Vergata D; Luz A; Coquery S; Daniel B; Ullman E; Franklin MC; Hermann A; Huang T; Olson W; Davis S; Murphy AJ; Sleeman MA; Wei J; Skokos D
Glycobiology; 2023 Aug; 33(7):591-604. PubMed ID: 37341346
[TBL] [Abstract][Full Text] [Related]
13. Pathogen clearance and immune adherence "revisited": Immuno-regulatory roles for CRIg.
van Lookeren Campagne M; Verschoor A
Semin Immunol; 2018 Jun; 37():4-11. PubMed ID: 29573978
[TBL] [Abstract][Full Text] [Related]
14. Extracellular stimulation of VSIG4/complement receptor Ig suppresses intracellular bacterial infection by inducing autophagy.
Kim KH; Choi BK; Kim YH; Han C; Oh HS; Lee DG; Kwon BS
Autophagy; 2016 Sep; 12(9):1647-59. PubMed ID: 27440002
[TBL] [Abstract][Full Text] [Related]
15. VISTA Stimulation of VSIG4-Positive Macrophages Strongly Suppresses T Cell Proliferation via Excessive Nitric Oxide Production in Sepsis.
Lee SW
Biol Pharm Bull; 2021 Nov; 44(11):1645-1652. PubMed ID: 34433706
[TBL] [Abstract][Full Text] [Related]
16. Antibodies Targeting Human or Mouse VSIG4 Repolarize Tumor-Associated Macrophages Providing the Potential of Potent and Specific Clinical Anti-Tumor Response Induced across Multiple Cancer Types.
Sazinsky S; Zafari M; Klebanov B; Ritter J; Nguyen PA; Phennicie RT; Wahle J; Kauffman KJ; Razlog M; Manfra D; Feldman I; Novobrantseva T
Int J Mol Sci; 2024 Jun; 25(11):. PubMed ID: 38892347
[TBL] [Abstract][Full Text] [Related]
17. Immune checkpoint protein VSIG4 as a biomarker of aging in murine adipose tissue.
Hall BM; Gleiberman AS; Strom E; Krasnov PA; Frescas D; Vujcic S; Leontieva OV; Antoch MP; Kogan V; Koman IE; Zhu Y; Tchkonia T; Kirkland JL; Chernova OB; Gudkov AV
Aging Cell; 2020 Oct; 19(10):e13219. PubMed ID: 32856419
[TBL] [Abstract][Full Text] [Related]
18. The biology of VSIG4: Implications for the treatment of immune-mediated inflammatory diseases and cancer.
Liu B; Cheng L; Gao H; Zhang J; Dong Y; Gao W; Yuan S; Gong T; Huang W
Cancer Lett; 2023 Jan; 553():215996. PubMed ID: 36343787
[TBL] [Abstract][Full Text] [Related]
19. Alternative pathway of complement activation by stimulated T lymphocytes. I. Binding of C3 fragments.
Sármay G; Ramos OF; Klein E; Kai C; Gergely J
Eur J Immunol; 1987 Jul; 17(7):969-74. PubMed ID: 3111862
[TBL] [Abstract][Full Text] [Related]
20. VSIG4 inhibits proinflammatory macrophage activation by reprogramming mitochondrial pyruvate metabolism.
Li J; Diao B; Guo S; Huang X; Yang C; Feng Z; Yan W; Ning Q; Zheng L; Chen Y; Wu Y
Nat Commun; 2017 Nov; 8(1):1322. PubMed ID: 29109438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
